News

The company has reported interim data from the pivotal phase 3 trial assessing Keytruda as both monotherapy and in combination with chemotherapy for the first-line treatment of recurrent

The GEOMETRY mono-1 study showed an overall response rate (ORR) of 72.0% (95% CI: 50.6-87.9) in treatment-naive patients and 39.1% (95% CI: 27.6-51.6) in previously treated patients. ORR

The committee has recommended Kalydeco to treat people with CF aged 12 to <24 months who have at least one of the following nine mutations in their cystic

The Phase III SOLO-1 trial assessed Lynparza as a maintenance treatment for patients with newly-diagnosed and advanced BRCA-mutated (BRCAm) ovarian cancer, who have been in complete or partial

New investors HBM Healthcare Investments (Cayman) and Nextech Invest also took part in the mezzanine financing, said TP Therapeutics. The new capital secured by the clinical-stage precision oncology

For patients with metastatic EGFR-mutated NSCLC, targeted EGFR TKI therapies such as gefitinib, erlotinib, afatinib or osimertinib represent the first-line treatment of choice. However, patients eventually develop resistance

Fibrosis occurs when chronic inflammation or persistent injury leads to the development of excessive connective tissue, which can lead to organ damage and impaired function. Fibrotic diseases can

As per terms of the deal, Novartis will purchase all outstanding shares of Endocyte common stock by paying $24 per share. Through using drug conjugation technology, Endocyte will

Earlier this month, the company said that Chronocort could not confirm its superiority over conventional treatment in endocrine control over a 24-hour period, which was the primary objective